Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06959095 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

Study acronym: ENDURA-1
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 1 entry Trial sites expanded: 15 → 281 locations · Primary completion moved earlier from Aug 20, 2029 to Dec 13, 2028 · Completion moved earlier from Aug 20, 2029 to Feb 14, 2029 · 3 more Show 6 more changesShow less
    • Trial sites expanded: 15 → 281 locations
    • Primary completion moved earlier from Aug 20, 2029 to Dec 13, 2028
    • Completion moved earlier from Aug 20, 2029 to Feb 14, 2029
    • Interventions modified
    • Eligibility criteria shortened, about 9 words
    • Study title shortened, about 2 words
  2. Study sites: 1 to 15v4
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary and study completion dates: Aug 6, 2029 to Aug 20, 2029 · Start date changed from estimate of Jun 6, 2025 to Jun 20, 2025v3 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Aug 6, 2029 to Aug 20, 2029
    • Start date changed from estimate of Jun 6, 2025 to Jun 20, 2025
  4. Enrollment target: 980 to 981 Study title expanded, about 2 wordsv2 Show 1 more changeShow less
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
245 trials monitored
See 20 trials at risk
COPD
1,068 trials monitored
See 31 trials at risk
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Trial Details
NCT Number NCT06959095
Lead Sponsor GlaxoSmithKline
Conditions Pulmonary Disease, Chronic Obstructive
Enrollment 981 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov